Attenuation, Near Resolution, and Prevention of Pruritus in Patients With Primary Biliary Cholangitis Treated With Seladelpar: A Secondary Analysis of Patterns of Pruritus Change in the RESPONSE Trial.
出版信息
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 12):4-6.
Abstract
摘要
相似文献
1
Attenuation, Near Resolution, and Prevention of Pruritus in Patients With Primary Biliary Cholangitis Treated With Seladelpar: A Secondary Analysis of Patterns of Pruritus Change in the RESPONSE Trial.塞地帕治疗原发性胆汁性胆管炎患者瘙痒的减轻、近期缓解及预防：RESPONSE试验中瘙痒变化模式的二次分析
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 12):4-6.
2
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.原发性胆汁性胆管炎中 Seladelpar 的 3 期临床试验。
N Engl J Med. 2024 Feb 29;390(9):783-794. doi: 10.1056/NEJMoa2312100. Epub 2024 Feb 21.
3
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.原发性胆汁性胆管炎患者在 3 个月时的塞拉莱德帕疗效和安全性：一项 3 期、随机、安慰剂对照研究（ENHANCE）。
Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6.
4
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.一项在原发性胆汁性胆管炎患者中进行的 II 期、随机、开放标签、52 周研究，评估 seladelpar 的疗效。
J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30.
5
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.塞拉得帕（MBX-8025），一种选择性过氧化物酶体增殖物激活受体 δ 激动剂，用于治疗对熊去氧胆酸应答不足的原发性胆汁性胆管炎患者：一项双盲、随机、安慰剂对照、2 期、概念验证研究。
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14.
6
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.Seladelpar 改善了原发性胆汁性胆管炎患者的瘙痒、睡眠和疲劳等症状，并降低了血清胆汁酸水平。
Liver Int. 2022 Jan;42(1):112-123. doi: 10.1111/liv.15039. Epub 2021 Aug 26.
7
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.Seladelpar 治疗可降低原发性胆汁性胆管炎患者的 IL-31 和瘙痒。
Hepatology. 2024 Jul 1;80(1):27-37. doi: 10.1097/HEP.0000000000000728. Epub 2023 Dec 20.
8
Seladelpar for the Treatment of Primary Biliary Cholangitis.塞拉达帕用于治疗原发性胆汁性胆管炎。
Ann Pharmacother. 2025 Mar 12:10600280251320069. doi: 10.1177/10600280251320069.
9
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis.评估 seladelpar 治疗原发性胆汁性胆管炎成人患者的安全性和疗效。
Expert Opin Pharmacother. 2024 Aug;25(11):1517-1523. doi: 10.1080/14656566.2024.2390120. Epub 2024 Aug 11.
10
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC).塞拉莱德帕：一种用于治疗早期原发性胆汁性胆管炎 (PBC) 的在研药物。
Expert Opin Investig Drugs. 2022 Oct;31(10):1101-1107. doi: 10.1080/13543784.2022.2130750. Epub 2022 Oct 8.
本文引用的文献
1
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.原发性胆汁性胆管炎中 Seladelpar 的 3 期临床试验。
N Engl J Med. 2024 Feb 29;390(9):783-794. doi: 10.1056/NEJMoa2312100. Epub 2024 Feb 21.
2
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.Seladelpar 治疗可降低原发性胆汁性胆管炎患者的 IL-31 和瘙痒。
Hepatology. 2024 Jul 1;80(1):27-37. doi: 10.1097/HEP.0000000000000728. Epub 2023 Dec 20.
3
Evaluation and Management of Pruritus in Primary Biliary Cholangitis.原发性胆汁性胆管炎瘙痒的评估和管理。
Clin Liver Dis. 2022 Nov;26(4):727-745. doi: 10.1016/j.cld.2022.06.009.
4
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.原发性胆汁性胆管炎患者瘙痒对生活质量的影响和当前的治疗模式。
Dig Dis Sci. 2023 Mar;68(3):995-1005. doi: 10.1007/s10620-022-07581-x. Epub 2022 Jun 15.
Zotero 插件